RecruitingNot Applicable

ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings

Australia6,000 participantsStarted 2018-05-28

Plain-language summary

The overall goals of the ETHOS II Project are to enhance hepatitis C virus (HCV) care in drug treatment clinics and needle and syringe programs (NSPs) in New South Wales and Australia, and to develop a translational framework for subsequent establishment of HCV screening and treatment programs in drug treatment clinics and NSPs across NSW and nationally.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant has voluntarily signed the informed consent form; * 18 years of age or older; * History of injecting drug use\*; * Recent injecting drug use (previous six months) or currently receiving OST\*. * These criteria will not apply for recruitment from residential rehabilitation centres Exclusion Criteria: * Nil

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Number of participants commencing anti-HCV treatment

Timeframe: Every year post enrolment for up to 3 years

Trial details

NCT IDNCT03685045

SponsorKirby Institute

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2026-12-31

Contact for this trial

David Silk, BSc

+61 2 9385 0878 dsilk@kirby.unsw.edu.au

View on ClinicalTrials.gov More Hepatitis C trials